Cost Of Alimta May Pose Problem In Europe -- MesoLink.org -- 09-02-04

The wonder drug that was approved by the Food and Drugs Administration for treatment of mesothelioma earlier this year is raising concerns due to its cost.

The drug has proven medical benefits but the cost is something that could potentially affect its chances of success in the European market.

Alimta was first approved for treatment on malignant mesothelioma early this year, and recently received approval for treatment in small cell lung cancer by the Food and Drugs Administration. This drug, manufactured by Eli Lilly, has been hailed a wonder drug by many people, and has given experts and cancer patients a ray of much-needed hope.

However, Lilly has confirmed that the drug is expected to cost around $3900 per month, and although the price will be marked down in Europe, it may still not prove cost effective.

The drug has not yet been approved in Europe but its price is likely to determine its success and uptake when it is approved.

Despite the cost associated with this drug, it has proven effective in trials and research to date, and there was a great deal of excitement when the drug was approved by the Food and Drugs Administration.

It is hoped that Alimta is one of many drugs that will prove beneficial for cancer sufferers, and the primary concern for most people is its efficiency rather than its price.